Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China flag China · Delayed Price · Currency is CNY
19.89
-0.79 (-3.82%)
Nov 17, 2026, 3:00 PM CST

Nanjing Vazyme Biotech Revenue

Nanjing Vazyme Biotech had revenue of 430.69M CNY in the quarter ending September 30, 2026, with 24.41% growth. This brings the company's total for the last twelve months to 1.56B, up 15.79% year-over-year. In the year 2025, Nanjing Vazyme Biotech had annual revenue of 1.38B. That makes Nanjing Vazyme Biotech the 16,401st largest company in the world by revenue and 2,970th in China.

Revenue (ttm)
1.56B
Revenue Growth
+15.79%
P/S Ratio
6.80
Revenue / Employee
518.53K
Employees
3,002
Market Cap
10.28B

Revenue Chart

Revenue by Segment

By Segment

Chart
  • Research and Experimental Development 1.17B 85.2%
  • Pharmaceutical Manufacturing 202.94M 14.8%

By Geography

Chart
  • China 1.20B 87.7%
  • Overseas 169.34M 12.3%
Fiscal year ended Dec 31, 2025 See the full Nanjing Vazyme Biotech breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20251.38B-16.98K-
Dec 31, 20241.38B91.91M7.15%
Dec 31, 20231.29B-2.28B-63.97%
Dec 31, 20223.57B1.70B90.99%
Dec 31, 20211.87B304.17M19.44%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.